Choline-containing supplement
Alpha-GPC
Alpha-GPC has no human half-life figure in the studies read; the app lists about 5 hours, and the trials report plasma choline, strength and cognition outcomes in single studies of 12 to 100 people.
Alpha-GPC after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.
Drawn from the half-life in the app's model, ~5 h. The model's figures
- Compound
- Alpha-GPC
- Symbol
- GPC
- Family
- Supplements
- Parts
- 13
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Alpha-GPC (alpha glyceryl phosphorylcholine, also called choline alphoscerate) is described in a 2023 meta-analysis as "a choline-containing phospholipid used as a medicine or nutraceutical".1 The app files it as a supplement in the choline sub-category, with an oral route, and grades the evidence as moderate. A 2026 Korean cohort study describes alpha-GPC as "widely prescribed for cognitive impairment and Alzheimer's dementia".2
No half-life or bioavailability figure for alpha-GPC in people appears in the records retrieved from PubMed for this compound, so the app's figures are shown without a matching figure from the records.
How it works
A 1992 pharmacokinetic study states that alpha-GPC's "mode of action is considered to involve the release of free choline, which is then utilized for acetylcholine and phosphatidylcholine biosynthesis in the brain".3 In rats given [14C]-labelled alpha-GPC intravenously (10 mg/kg) or orally (100-300 mg/kg), Abbiati and colleagues wrote "It is assumed that alpha-GPC is hydrolyzed by phosphodiesterases in the gut mucosa".4 In the same rat study, radioactivity in the brain was "comparable to" or "lower than" total blood radioactivity depending on the label, and choline "was incorporated into brain phospholipids in increasing amounts within 24 h of dosing".4 Bellar and colleagues, introducing their 2015 trial, state that "Ingested A-GPC is converted to phosphatidylcholine, a source of choline" and propose that raised choline availability "may result in augmented acetylcholine synthesis in neurons"; their trial did not measure either step.5 In mice, Wang and colleagues (Cleveland Clinic, 2021) report that "GPC can be metabolized to trimethylamine N-oxide, a pro-atherogenic agent", and that GPC promoted atherosclerosis in hyperlipidemic Apoe-/- mice; this is an animal and cell result, not a finding in people.6 In 12 healthy men given single doses of glycerophosphocholine (GPC) or soy-derived lysophosphatidylcholine, Tanaka-Kanegae and colleagues (Otsuka Pharmaceutical, 2024) report that "neither of them significantly elevated plasma trimethylamine N-oxide concentration".7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~5 h
- Bioavailability
- 90%
- Typical dose
- 300–600 mg/day
- Route
- Oral
- Time to peak
- ~1.5 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the records report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~5 h | No half-life for alpha-GPC in people was identified in the PubMed records retrieved |
| Bioavailability | 90% | No oral bioavailability figure for alpha-GPC in people was identified; in rats the radiolabelled compound's absorption was described after oral doses of 100-300 mg/kg4 |
| Time to peak | ~1.5 h | After a single intramuscular 1,000 mg dose in 12 volunteers, plasma choline peak levels were usually observed at the 0.25 h or 0.5 h sample (an injected route, and a choline measurement)3 |
| Duration of action | 8 h | No duration for alpha-GPC in people was identified |
Gatti and colleagues (University of Pavia, 1992) gave 12 normal volunteers 1,000 mg of alpha-GPC or 1,000 mg of citicoline intramuscularly on separate days, with a control day, and sampled plasma choline over 6 hours.3 After alpha-GPC the concentration "declined gradually and returned to near baseline values at the end of the observation period", and after citicoline plasma choline "showed a similar time course but were considerably lower".3 Tanaka-Kanegae and colleagues report that both glycerophosphocholine and the lysophosphatidylcholine product "increased plasma choline, serum phospholipid, and serum triglyceride concentrations" after a single dose in 12 healthy men; the record read gives no half-life for glycerophosphocholine, and the record does not say whether the compound was the alpha form.7
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Bellar and colleagues, J Int Soc Sports Nutr 20155 | Double-blind, placebo-controlled crossover, one-week washout; funded by Chemi Nutra5 | 13 healthy college-aged males5 | 600 mg per day of A-GPC or placebo; 6 days5 | Isometric mid-thigh pull peak force change from baseline 98.8 ± 236.9 N with A-GPC against -39.0 ± 170.9 N with placebo (p = 0.044); upper-body test not significant (p = 0.127); no effect on the mid-thigh pull 1 h after the first dose (interaction p = 0.738)5 |
| Kerksick, Nutrients 20248 | Randomized, double-blind, placebo-controlled crossover; NNB Nutrition grant, and the author is a paid scientific advisor to that sponsor8 | 20 resistance-trained males, mean age 31.3 ± 11.0 years8 | Single dose of placebo, 315 mg or 630 mg A-GPC; cognitive tests 60 min later8 | Stroop total score change 13.0 ± 8.2 (630 mg) and 10.8 ± 7.7 (315 mg) against 5.2 ± 9.0 (placebo), p = 0.013 and p = 0.046; no significant differences on Flanker accuracy or N-Back; no group differences in visual analog scales or growth hormone; bench press peak force showed no one-way ANOVA difference (p = 0.159), with a post hoc comparison putting 630 mg above placebo (p = 0.043)8 |
| Jeon and colleagues, BMC Geriatrics 20249 | Multicentre, randomized, double-blind, placebo-controlled; supported by Suheung9 | 100 adults with mild cognitive impairment enrolled (52 alpha-GPC, 48 placebo); 42 and 32 analysed for the primary and secondary outcomes9 | 600 mg alpha-GPC (SHCog soft capsule) or placebo; 12 weeks9 | ADAS-cog change -2.34 ± 3.26 with alpha-GPC against -0.97 ± 2.32 with placebo; difference in total MoCA-K not significant (p = 0.105); no serious adverse events9 |
| Sagaro and colleagues, J Alzheimers Dis 20231 | Systematic review and meta-analysis of 7 randomized trials and 1 prospective cohort; institutional funding1 | 861 participants with adult-onset cognitive impairment, in 8 studies1 | Oral 1,200 mg per day; 90 to 180 days in the three trials behind the 3.50 estimate, 360 to 720 days in the donepezil trials1 | MMSE mean difference 3.50 (95% CI 0.36 to 6.63, I2 = 98%, 3 trials) against placebo or other drugs; with donepezil 1.72 (95% CI 0.20 to 3.25, I2 = 61%, 4 trials); no significant difference on the BADL1 |
| Gatti and colleagues, Int J Clin Pharmacol Ther Toxicol 19923 | Randomized, three sessions (control day, alpha-GPC, citicoline), washout of at least 1 week3 | 12 normal volunteers3 | Single intramuscular 1,000 mg; 6 h sampling3 | Plasma choline peak levels usually observed at 0.25 h or 0.5 h and near baseline values at the end of the 6 h observation; citicoline gave lower levels3 |
| Tanaka-Kanegae and colleagues, Biosci Biotechnol Biochem 20247 | Randomized single-dose pharmacokinetic comparison against soy oil placebo and soy-derived lysophosphatidylcholine; Otsuka Pharmaceutical grant, and all three authors are affiliated with Otsuka Pharmaceutical7 | 12 healthy men7 | Single dose of glycerophosphocholine (GPC; the record does not say whether it was the alpha form) at the same choline amount as 480 mg lysophosphatidylcholine7 | Plasma choline increased; plasma trimethylamine N-oxide not significantly elevated7 |
| Park and colleagues, Cancer Epidemiol 20262 | Retrospective cohort, Korean National Health Insurance Service data, 1:5 propensity matching; no conflicts declared2 | 81,970 alpha-GPC users and 409,801 non-users aged 50 or older who underwent health screening in 2009-20102 | Use recorded in insurance data (dose not given in the record); events 2011 to 20242 | Kidney cancer adjusted HR 0.95 (95% CI 0.84-1.08); 280 events in users, 1570 in non-users2 |
Deeper analysis: Bellar and colleagues, 2015
Bellar and colleagues (School of Kinesiology, University of Louisiana at Lafayette) reported a trial in the Journal of the International Society of Sports Nutrition in 2015.5 It was "a double-blind, placebo-controlled crossover with a 1-week washout period" in 13 healthy, college-aged males who took 600 mg of A-GPC or placebo daily.5 Testing was done at baseline, 1 hour after a first dose in the laboratory, and on day 6, using an isometric mid-thigh pull and an upper-body isometric test.5 The acute result was null: the analysis "did not reveal any main effects (F = 0.003, p = 0.9584) nor interaction effects of treatment*time (F = 0.114, p = 0.738)" for the mid-thigh pull 1 hour after the first dose.5 After 6 days, the authors report "significantly greater isometric mid thigh pull peak force change from baseline (t = 1.76, p = 0.044) compared with placebo", with changes of 98.8 ± 236.9 N and -39.0 ± 170.9 N.5 The upper-body test "failed to obtain statistical significance (t = 1.16, p = 0.127)".5 The authors also used magnitude-based inference and report that A-GPC was "68.3 % likely beneficial for increasing upper body isometric force and 86.5 % likely beneficial for increasing lower body isometric force production", while writing that this interpretation "is not without controversy".5 Their stated limitations include that "The present investigation is limited by sample size" and that "The study will need to be replicated with larger study populations".5 Funding came from Chemi Nutra; the authors state that no person employed by or affiliated with Chemi Nutra had any role in the design of the study, interpretation of the data or development of the manuscript, and they declare no competing financial interests.5 The A-GPC product was "AlphaSize®, ChemiNutra", and the text of the paper does not report adverse events.5
Deeper analysis: Kerksick, 2024
Kerksick (Lindenwood University) reported a randomized, double-blind, placebo-controlled crossover trial in Nutrients in 2024, in which 20 resistance-trained males took placebo, 630 mg or 315 mg of A-GPC.8 Cognitive tests (Stroop, N-Back and Flanker) and visual analog scales were done 60 minutes after the dose, then the men did lower-body resistance exercise, with growth hormone sampled at 5, 15, 30 and 60 minutes afterwards.8 The Stroop total score "increased to a statistically significantly greater degree in HD (13.0 ± 8.2; p = 0.013, d = 0.61) and LD (10.8 ± 7.7; p = 0.046, d = 0.48) when compared to PL (5.2 ± 9.0)".8 The Stroop completion time was faster on the 630 mg dose than on placebo (-0.12 ± 0.09 s against -0.05 ± 0.09 s, p = 0.021), while the 315 mg dose showed a trend (p = 0.072).8 The secondary and null results were: no significant differences on Flanker accuracy and incompatible reaction time or on N-Back, and no differences in mood, alertness or concentration scales.8 Bench press peak force showed no one-way ANOVA difference (p = 0.159), though a post hoc comparison put the 630 mg dose above placebo (p = 0.043).8 Growth hormone area under the curve did not differ: "HD: 380 ± 279, LD: 414 ± 273, PL: 351 ± 272 ng/mL/min, p = 0.438".8 The author writes that "In contrast to the results provided by Ziegenfuss et al. , no differences in growth hormone concentrations were observed in the present study".8 The stated limitations include that "using more rigorous correction for pairwise comparisons may have impacted our final outcomes", that "Another key limitation was the single dose delivered as part of this study design", and that only males were recruited.8 The paper states "Funding was provided by Nanjing Nutrabuilding Bio-tech Co., Ltd. (NNB Nutrition, Nanjing, China) through a restricted grant to The Center for Applied Health Sciences", and that "The author (CK) serves as a paid scientific advisor for the sponsor of this study (NNB Nutrition)", with a conflict-of-interest management plan.8 The registry entry names Lindenwood University as lead sponsor with NNB Nutrition as a collaborator, and was first submitted on 2024-11-12, after the study ran from 2024-01-09; the paper says it was "retrospectively registered".10 Adverse events: "Ten participants experienced AEs that were mild to moderate in nature", with "no differences in proportions of reported adverse events" between treatments; the table lists 2 of 20 (10%) on 630 mg, 4 of 21 (19%) on 315 mg and 4 of 20 (20%) on placebo.8
Deeper analysis: Jeon and colleagues, 2024
Jeon and colleagues (Myongji Hospital, Hanyang University, and Yonsei University, Korea) reported a trial in BMC Geriatrics in 2024, registered as KCT0008797.9 It enrolled 100 people with mild cognitive impairment, 52 given alpha-GPC (600 mg in a SHCog soft capsule) and 48 given placebo, for 12 weeks, with the ADAS-cog change as the primary outcome.9 The methods state that analysis used an intention-to-treat dataset, while the results state "For the primary and secondary outcomes, 42 subjects in the αGPC group and 32 subjects in the placebo group were analyzed" and that 74 subjects (74%) were in the per-protocol population.9 Both groups improved on the ADAS-cog (alpha-GPC -2.34 ± 3.26; placebo -0.97 ± 2.32), and "The decrease in the ADAS-cog score was significantly greater in the αGPC group" than in the placebo group, with the p-value printed as lower than 0.048.9 Among secondary outcomes, language-naming on the MoCA-K improved more with alpha-GPC (p = 0.003) and color-naming time on the Stroop test differed (p = 0.048), while the total MoCA-K, instrumental activities of daily living (p = 0.467), subjective cognitive decline (p = 0.343) and depression scale (p = 0.560) did not differ between groups.9 Safety: "No serious AEs were reported, and no participants discontinued the intervention because of AEs", the most common adverse events in both groups were gastrointestinal, and "All AEs reported in both groups resolved completely".9 The stated limitations include that "the 12-week duration was not enough to capture the full spectrum of" the effects and that "the diagnosis of MCI relied solely on clinical assessment tools"; the authors add that "recent cohort studies have reported an association with stroke" and that long-term monitoring is needed.9 The trial was "supported by the Suheung", one author lists Suheung Technology Research Institute as an affiliation, and the authors "declare no competing interests".9
Meta-analysis of dementia trials
Sagaro and colleagues (University of Camerino, 2023) searched PubMed, Web of Science and Embase and included seven randomized trials and one prospective cohort study.1 They report an effect on cognition with alpha-GPC plus donepezil (MMSE mean difference 1.72, 95% CI 0.20 to 3.25, 4 trials, I2 = 61%) and a difference against placebo or other medications (MMSE mean difference 3.50, 95% CI 0.36 to 6.63, 3 trials of 449 participants, I2 = 98%).1 In their discussion, a pooled analysis of alpha-GPC plus donepezil found "no significant difference" on the basic activities of daily living scale, and for two studies they "considered an assigned value of 0.7 in the formula to calculate the SD change", which "may limit the certainty of our pooled findings".1 Funding was institutional (University of Camerino) and the authors report no conflict of interest.1
Registered trials with no journal report identified
The registry entries below were read; no journal report of these three trials was identified in the PubMed queries run for this compound, and none of the entries posts results.
- NCT03903250 (University of Mary Hardin-Baylor, with Chemi Nutra, LLC. as collaborator): "Effects of A-GPC on Reaction Time and Cognitive Function Under Acute Sleep-Deprived Conditions", randomized, double-masked crossover, 18 enrolled, status COMPLETED.11
- NCT02886130 (Université de Montréal): alpha-GPC or maltodextrin in varsity volleyball players, randomized crossover, 28 enrolled, status COMPLETED; the alpha-GPC arm is described as "Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration".12
- NCT07267845 (Nanjing Nutrabuilding Bio-tech Co., Ltd., the sponsor of the Kerksick product): randomized, quadruple-masked, parallel-group, 81 enrolled, status COMPLETED; the arm takes "one capsule containing 350 mg of GeniusPure® (containing 315 mg of pure α-GPC) daily before breakfast for 6 weeks" against microcrystalline cellulose.13
Doses reported in studies and on labels
The app's typical dose is 300 to 600 mg/day. No US label for alpha-GPC was identified in DailyMed, so the doses below come from studies and registry entries.
| Reference | Dose and route | Length | People and comparator |
|---|---|---|---|
| Bellar and colleagues 20155 | 600 mg per day of A-GPC by mouth, morning and evening | First dose, then 6 days | 13 healthy males; placebo crossover |
| Kerksick 20248 | 315 mg or 630 mg A-GPC by mouth, single dose | Single dose | 20 resistance-trained males; placebo crossover |
| Jeon and colleagues 20249 | 600 mg alpha-GPC (SHCog soft capsule), by mouth, once daily | 12 weeks | 100 adults with mild cognitive impairment; placebo |
| NCT07267845 registry entry13 | 350 mg capsule containing 315 mg of pure alpha-GPC, daily before breakfast | 6 weeks | 81 adults enrolled; microcrystalline cellulose placebo |
| NCT02886130 registry entry12 | 250 mg tablets, 2 in the morning and 2 before workout, by mouth | 4 weeks | 28 varsity volleyball players; maltodextrin comparator |
| Trials in the Sagaro meta-analysis1 | 1,200 mg per day by mouth in three randomized trials | 90 to 180 days | Adults with adult-onset dementia disorders of neurological origin; placebo or ST200 comparators |
| Gatti and colleagues 19923 | 1,000 mg alpha-GPC by intramuscular injection | Single dose, 6 h sampling | 12 normal volunteers; citicoline and no-drug control days |
Side effects reported
In Kerksick's crossover trial of single doses, "Ten participants experienced AEs that were mild to moderate in nature", with events including nausea, emesis, headache and lightheadedness spread across all three treatments, and the author attributes most to study procedures rather than the product.8 In the 12-week trial in mild cognitive impairment, no serious adverse events and no discontinuations for adverse events were reported, and the most common events in both groups were gastrointestinal.9 The text of Bellar's 6-day trial does not report adverse events.5 Wang and colleagues note a cohort of "more than 12 million human subjects" in which "the use of GPC was associated with a higher 10-year incident stroke risk in a dose-response manner"; this is their secondhand description of another study, and their own experiments were in mice and cultured human coronary artery endothelial cells, with human fecal samples from the HELIUS study also mentioned.6 Wang and colleagues close by calling for caution with GPC as a nutritional supplement and write that "Further studies are needed to confirm these recent findings with larger clinical cohorts".6 Funding for Wang and colleagues is listed as NIH and Office of Dietary Supplements grants, an Estonian Research Council grant, a ZONMW grant and Leducq Foundation support; their conflict statement says Wang and Hazen are named as co-inventors on Cleveland Clinic patents and have received royalty payments from Cleveland Heart Lab and Procter & Gamble, and that Hazen is a paid consultant for Procter & Gamble and Zehna Therapeutics.6 Park and colleagues, in a Korean cohort of 81,970 users and 409,801 non-users, found that "α-GPC use was not associated with kidney cancer risk (adjusted HR 0.95, 95% CI 0.84-1.08; 280 events in α-GPC users, 1570 in non-users)"; they also note that "Further studies in diverse populations are warranted".2
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for alpha-GPC. In the 12-week trial in mild cognitive impairment, uric acid rose significantly against placebo (p = 0.024) and total cholesterol showed a rising trend (p = 0.033), without clinically meaningful changes according to the authors.9
Regulatory and anti-doping status
Sources in this part
The 2026 WADA Prohibited List came into effect on 1 January 2026.14 A text search of the 2026 list for "choline" and "glycerylphosph" returned no match, so alpha-GPC is not named on it; the list names growth hormone secretagogues and their mimetics under S2.2.4.14 The 2027 list was not read for this entry. No US label for alpha-GPC was identified in DailyMed. A 2023 meta-analysis states that, "Despite its 1985 marketing authorization, there are still discrepancies between countries regarding its approval as a prescription medicine".1
What is not known
Sources in this part
- No half-life, bioavailability or time to peak for oral alpha-GPC in people was identified in the PubMed records retrieved, so the app's 5 hours, 90% and 1.5 hours stand without a figure from the records beside them.
- The app's notes cite a power increase of about 14% in some studies; none of the studies read reports that figure, and Bellar and colleagues report "greater than a 3 % increase in lower body isometric strength".5
- Whether alpha-GPC raises growth hormone is not settled by the records read: Kerksick reports no difference and notes that this contrasts with an earlier study.8
- The trials in healthy people were single-dose or lasted 6 days, and Kerksick notes that only males were recruited.8
- The app's note that alpha-GPC stacks with racetams to avoid choline-deficiency headaches had no study in the records read.
Frequently asked questions
What is the half-life of alpha-GPC?
The app lists a half-life of about 5 hours, and no half-life for alpha-GPC in people was identified in the PubMed records retrieved. After a single 1,000 mg intramuscular dose, plasma choline returned to near baseline by the end of 6 hours of sampling.3
Is alpha-GPC banned by WADA?
What is alpha-GPC?
A 2023 meta-analysis describes alpha-GPC as "a choline-containing phospholipid used as a medicine or nutraceutical".1
Does alpha-GPC increase growth hormone?
Does alpha-GPC increase strength?
Does alpha-GPC improve cognition in trials?
In Kerksick's trial, Stroop total score rose more with 630 mg and 315 mg than with placebo, while Flanker accuracy and N-Back showed no significant differences.8 In Jeon and colleagues' 12-week trial in mild cognitive impairment, the ADAS-cog fell by 2.34 ± 3.26 with alpha-GPC and 0.97 ± 2.32 with placebo, in an analysis of 42 and 32 people.9
Is alpha-GPC linked to stroke?
Wang and colleagues describe another cohort as reporting that "the use of GPC was associated with a higher 10-year incident stroke risk in a dose-response manner", and their own work was in mice and cells.6
Is alpha-GPC linked to kidney cancer?
In a Korean cohort of adults aged 50 or older who underwent health screening in 2009-2010 (81,970 users and 409,801 non-users), "α-GPC use was not associated with kidney cancer risk (adjusted HR 0.95, 95% CI 0.84-1.08; 280 events in α-GPC users, 1570 in non-users)".2
Guides, tools and comparisons
References
- Sagaro GG, Traini E, Amenta F. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2023. PMID 36683513
- Park YJ, et al. Association between L-α-glycerylphosphorylcholine use and risk of kidney cancer: A nationwide representative retrospective cohort study. Cancer Epidemiol 2026. PMID 42361543
- Gatti G, et al. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol 1992. PMID 1428296
- Abbiati G, et al. Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine. Eur J Drug Metab Pharmacokinet 1993. PMID 8243501
- Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr 2015. PMID 26582972
- Wang Z, et al. The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis. Int J Mol Sci 2021. PMID 34948275
- Tanaka-Kanegae R, et al. Pharmacokinetics of soy-derived lysophosphatidylcholine compared with that of glycerophosphocholine: a randomized controlled trial. Biosci Biotechnol Biochem 2024. PMID 38490741
- Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients 2024. PMID 39683633
- Jeon J, et al. Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatr 2024. PMID 39300341
- Lindenwood University. Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function. ClinicalTrials.gov NCT06690619. NCT06690619
- University of Mary Hardin-Baylor. Effects of A-GPC on Reaction Time and Cognitive Function. ClinicalTrials.gov NCT03903250. NCT03903250
- Université de Montréal. Alpha-GPC and Physical and Cognitive Performances in Volleyball Players. ClinicalTrials.gov NCT02886130. NCT02886130
- Nanjing Nutrabuilding Bio-tech Co., Ltd. The Effect of α-GPC on Cognitive Function and Sports Performance. ClinicalTrials.gov NCT07267845. NCT07267845
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list